ArticleGeneral thoracic and cardiovascular surgery2026
Safety and efficacy of simple system for artificial chordae length adjustment in patients undergoing minimally invasive mitral valve repair.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor patients who require mitral valve repair, it is often difficult to determine the appropriate artificial chordae length. The Memo 3D/4D ReChord system, developed for use as a temporary chordal guide system, is comprised of a complete prosthetic ring containing yellow loops that function as a reference for automatically determining neo-chordae height. The present study was conducted to evaluate the safety and efficacy of this system when used with a minimally invasive right mini-thoracotomy approach.
methodsSixty-three patients (40 males, 64.4 ± 13.3 years old) using this system were enrolled. Preoperative status and operative procedures, as well as early- and mid-term results were assessed.
resultsThe number of artificial chordae was one in 19, two in 39, and three in 5 cases. In 33 patients, the treatment was completed with use of the ReChord system alone, while 30 required additional procedures. Mitral valve repair was successfully performed in all and there were no mortalities. Postoperative echocardiography mitral regurgitation grade was none in 16 and mild in 47. Two patients required repeat mitral valve surgery. Five- and seven-year survival rates were 93.3% and 90%, respectively, and the rates for freedom from reoperation after five and seven years were 95.3%, and 95.3%, respectively.
conclusionsMitral valve repair with the Memo 3D/4D ReChord system provides for easy adjustment of the artificial chordae, with acceptable early and mid-term results noted in the present cases. This useful system is considered to be an effective option for a minimally invasive right thoracotomy approach.
Indexed as
Identifiers
41489679What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.